RE:RE:RE:RE:TomorrowI would disagree that this test is beating Sona to market unless you think the only market is the US.
Sona is a global play with LOI's already in place in multiple countries on multiple continents. FDA and HC approval immenent.
The true market is big enough for several players and hopefully Sona and VST get a piece. But make no mistake, VST isnt beating Sona to market.
We also at this point dont know VST manufacturing capabilities (volume and timeline of delivery etc.) whereas Sona has confirmed the ability to reach 1 billion tests per annum and currently would be able to deliver 100 million tests per annum.
I dont think Sona considers VST a competitor at this stage but thats just my opinion. I have held both for quite some time.
GLTA longs